[Selective adhesion molecule inhibitors. Natalizumab in multiple sclerosis and Crohn's disease].
Hennemann
Alexandra
A
ahennemann@wissenschaftliche-verlagsgesellschaft.de
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D000069442:Natalizumab